ID   HT-29_6244R
AC   CVCL_C3GK
SY   HT6244-R
DR   cancercelllines; CVCL_C3GK
DR   Wikidata; Q114311670
RX   PubMed=31048689;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31048689; DOI=10.1038/s41467-019-09438-w;
RA   Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K.,
RA   McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G.,
RA   Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J.,
RA   Saez-Rodriguez J., Smith P.D., Cook S.J.;
RT   "MEK1/2 inhibitor withdrawal reverses acquired resistance driven by
RT   BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes
RT   EMT-chemoresistance.";
RL   Nat. Commun. 10:2030.1-2030.22(2019).
//